We are live on ! Find out more
FLSM

Frazier Life Sciences Management Portfolio holdings

AUM $3.89B
1-Year Est. Return 201.1%
This Fund
S&P 500
This Quarter Est. Return
+13.35%
1 Year Est. Return
+201.1%
3 Year Est. Return
+879.31%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.41B
AUM Growth
-$85.8M
Cap. Flow
-$78.4M
Cap. Flow %
-3.25%
Top 10 Hldgs %
66.5%
Holding
55
New
2
Increased
13
Reduced
9
Closed
5

Top Buys

1
NAMS icon
NewAmsterdam Pharma
NAMS
+$65M
2
PLRX icon
Pliant Therapeutics
PLRX
+$15.3M
3
KALV
KalVista Pharmaceuticals
KALV
+$12.4M
4
TRVI icon
Trevi Therapeutics
TRVI
+$10.5M
5
PVLA
Palvella Therapeutics
PVLA
+$10M

Top Sells

1
EWTX icon
Edgewise Therapeutics
EWTX
+$49.7M
2
KRYS icon
Krystal Biotech
KRYS
+$35.5M
3
PCVX icon
Vaxcyte
PCVX
+$33.8M
4
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$30.2M
5
TYRA icon
Tyra Biosciences
TYRA
+$17.2M

Sector Composition

1 Healthcare 99.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCKT icon
26
Rocket Pharmaceuticals
RCKT
$372M
$18.6M 0.77%
1,479,025
-6,605
-0.4% -$99.4K
ASND icon
27
Ascendis Pharma A/S
ASND
$17B
$18.4M 0.76%
133,333
– –
MREO
28
Mereo BioPharma
MREO
$51.5M
$17.8M 0.74%
5,097,779
– –
ALKS icon
29
Alkermes
ALKS
$8.66B
$17.3M 0.72%
601,129
+25,000
+4% +$719K
MRUS
30
DELISTED
Merus
MRUS
$15.7M 0.65%
373,100
– –
IMTX icon
31
Immatics
IMTX
$1.28B
$15.3M 0.63%
2,147,911
+793,200
+59% +$6.82M
PLRX icon
32
Pliant Therapeutics
PLRX
$68.7M
$14.8M 0.61%
+1,120,803
New +$15.3M
DSGN icon
33
Design Therapeutics
DSGN
$788M
$12.1M 0.5%
1,953,547
+61,000
+3% +$353K
ORKA
34
Oruka Therapeutics
ORKA
$5.01B
$11.3M 0.47%
583,327
+106,000
+22% +$2.59M
AUTL
35
Autolus Therapeutics
AUTL
$389M
$10.9M 0.45%
4,623,324
– –
MGNX icon
36
MacroGenics
MGNX
$262M
$10.3M 0.43%
3,175,665
+164,938
+5% +$594K
DAWN
37
DELISTED
Day One Biopharmaceuticals
DAWN
$8.74M 0.36%
689,655
– –
ACAD icon
38
Acadia Pharmaceuticals
ACAD
$4.39B
$8.63M 0.36%
470,338
– –
SLN
39
Silence Therapeutics
SLN
$516M
$7.9M 0.33%
1,148,591
– –
PVLA
40
Palvella Therapeutics
PVLA
$2.12B
$7.85M 0.33%
653,892
+637,950
+4,002% +$10M
ETNB
41
DELISTED
89bio
ETNB
$7.82M 0.32%
1,000,000
– –
COGT icon
42
Cogent Biosciences
COGT
$6.48B
$7.31M 0.3%
936,576
– –
NAMSW icon
43
NewAmsterdam Pharma Warrant
NAMSW
$94.6M
$7.13M 0.3%
500,333
– –
LXEO icon
44
Lexeo Therapeutics
LXEO
$358M
$6.29M 0.26%
955,515
-295,271
-24% -$2.33M
ALLO icon
45
Allogene Therapeutics
ALLO
$618M
$6.11M 0.25%
2,867,750
– –
ARVN icon
46
Arvinas
ARVN
$518M
$5.47M 0.23%
285,331
– –
ADVM
47
DELISTED
Adverum Biotechnologies
ADVM
$4.99M 0.21%
1,069,244
– –
ELDN icon
48
Eledon Pharmaceuticals
ELDN
$296M
$4.85M 0.2%
+1,176,735
New +$4.64M
ELEV
49
DELISTED
Elevation Oncology
ELEV
$3.37M 0.14%
5,993,579
– –
IMCR icon
50
Immunocore
IMCR
$1.75B
$3.21M 0.13%
108,762
– –
1
2
3

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $3.88B AUM 23.82% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
CCM
Channing Capital Management Chicago, Illinois $3.91B AUM 34.32% 1-Year Est. Return
TFM
Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
AA
Alesco Advisors Pittsford, New York $3.92B AUM 15.21% 1-Year Est. Return
DACG
Donor Advised Charitable Giving San Francisco, California $3.92B AUM 59.92% 1-Year Est. Return

Frazier Life Sciences Management's Q4 2024 Portfolio in Review

As of Q4 2024, Frazier Life Sciences Management held 55 positions worth $2.41B, down 3.4% from $2.5B the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Frazier Life Sciences Management withdrew a net $78.4M in Q4 2024, closing 5 positions and reducing 9 holdings. Its most notable exit was Tyra Biosciences, an estimated $17.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

Against the trend, Frazier Life Sciences Management opened a new position in Pliant Therapeutics worth $14.8M.

  • Frazier Life Sciences Management's largest Q4 2024 buy was Pliant Therapeutics: 1,120,803 shares worth $14.8M.
  • Frazier Life Sciences Management added most to NewAmsterdam Pharma in Q4 2024, an estimated $65M increase.
  • Frazier Life Sciences Management's biggest Q4 2024 reduction was Edgewise Therapeutics, cutting an estimated $49.7M.
  • Frazier Life Sciences Management fully exited Tyra Biosciences in Q4 2024, selling an estimated $17.2M.
  • Frazier Life Sciences Management's ten largest holdings make up 67% of its $2.41B portfolio in Q4 2024.
  • Frazier Life Sciences Management opened 2 new positions and closed 5 in Q4 2024.
  • Frazier Life Sciences Management's portfolio value fell 3.4% quarter-over-quarter to $2.41B.

Based on Frazier Life Sciences Management's 13F filing for Q4 2024, filed 18 Feb 2025.